Antengene Closes US$97M Series C Financing
Summary
Antengene Corporation, a Shangai, China-based hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, closed US$97m Series C financing round. Led by Dr. Jay Mei, Founder, Chairman and CEO, Antengene is a biopharmaceutical company with integrated drug discovery, clinical development, manufacturing and commercialization anchored in the Asia Pacific regions and with a global layout. In April 2017, Celgene (now officially acquired by Bristol-Myers Squibb), a global innovative biopharmaceutical company became a founding partner and obtained an equity position as an investor in Antengene. The company intends to use the funds for the continuing clinical development of its pipeline of hematology and oncology therapies, expanding in-house research and development capabilities and strengthening the commercial infrastructures in APAC markets. To date, Antengene has made significant progress with its broad pipeline of six clinical-stage programs and six pre-clinical stage oncology assets: